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Background: No published data exist about the safety of diagnostic magnetic resonance (MR) of the heart
performed in a larger series of patients implanted with MR conditional pacemakers (PM). The purpose of our study
is to analyse safety and potential alterations of electrical lead parameters in patients implanted with the EnRhythm/
Advisa MRI SureScan PM with 5086MRI leads (Medtronic Inc.) during and after MR of the heart at 1.5 Tesla.
Methods: Patients enrolled in this single center pilot study who underwent non-clinically indicated diagnostic MR
of the heart were included in this analysis. Heart MR was performed for analyses of potential changes in right and
left ventricular functional parameters under right ventricular pacing at 80 and 110 bpm. Atrial/ventricular sensing,
atrial/ventricular pacing capture threshold [PCT], and pacing impedances were assessed immediately before, during,
and immediately after MR, as well at 3 and 15 months post MR.
Results: Thirty-six patients (mean age 69 ± 13 years; high degree AV block 18 [50%]) underwent MR of the heart.
No MR related adverse events occurred during MR or thereafter. Ventricular sensing differed significantly between
the FU immediately after MR (10.3 ± 5.3 mV) and the baseline FU (9.8 ± 5.3 mV; p < 0.05). Despite PCT [V/0.4ms]
was not significantly different between the FUs (baseline: 0.84 ± 0.27; in-between MR scans: 0.82 ± 0.27; immediately
after MR: 0.84 ± 0.24; 3-month: 0.85 ± 0.23; 15-month: 0.90 ± 0.67; p = ns), 7 patients (19%) showed PCT increases
by 100% (max. PCT measured: 1.0 V) at the 3-month FU compared to baseline. RV pacing impedance [Ω/5V]
differed significantly at the FU in-between MR scans (516 ± 47), and at the 15-month FU (482 ± 58) compared to
baseline (508 ± 75).
Conclusion: The results of our study suggest MR of the heart to be safe in patients with the MR conditional
EnRhythm/Advisa system, albeit although noticeable but clinically irrelevant ventricular PCT changes were observed.
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Magnetic resonance (MR) evolved into an important
diagnostic tool for diagnosis and therapy control of cer-
tain diseases especially affecting soft tissues [1]. Due to
safety concerns MR in patients with cardiac implantable
electronic devices (CIEDs) is not recommended except
in the case of vital indication [2]. Some larger series of
MR at 1.5 Tesla (T) in patients implanted with standard
pacemakers (PM) demonstrated safety of even repetitive
procedures when certain precautions are taken [3-8]. All
of the leading pacemaker manufacturers are now offer-
ing MR conditional pacemaker systems. Patients im-
planted with these MR conditional pacemaker systems
may undergo MR under certain precautions and condi-
tions [9]. The potentially hazardous MR effects on
CIEDs are based on the three components of MR tech-
nology, the static magnetic field, the switched gradient
magnet fields, and the pulsed radio frequency fields. The
effects are dependent on magnet field strength and RF
power, and are modulated by patient specific characteris-
tics (e.g. size, anatomy), the patient’s position in the MR
bore, as well CIED hardware related characteristics (e.g.
lead position, lead design). One major concern in MR in
patients with permanent pacemaker and ICDs is lead tip
heating resulting in damage of the adjacent cardiac tis-
sue, resulting in PCT increases. Reversion to back up
mode is rare but may lead to pacemaker inhibition dur-
ing MR [4].
The closer the device to the imaging landmark is, the
more hazardous on patients health some of the above
described MR related effects can become due to deteri-
oration of the implanted systems function and/or behav-
iour. Nordbeck et al. demonstrated in an in vitro study
at 1.5T that electric field magnitudes decrease with re-
duced RF coupling (and, therefore decreased risk for po-
tential device heating), e.g. by increasing the distance
between the area of interest and imaging landmark [10].
Shellock et al. demonstrated in an in vitro model at 1.5T
highest temperature increases at the “ventricular” tip
electrode when the imaging landmark was within the
thorax region of a phantom [11].
To overcome the potentially hazardous effects of MR
on pacemaker systems, MR conditional pacemakers have
modified material composition (e.g. reduced ferro-magnetic
components, Hall instead of Reed switch) and have add-
itional programming features (e.g. one-button deactivation
of certain pacemaker functions, asynchronous pacing mode
etc.) to ensure safety.
The knowledge about all these possible hazards of MR
on CIEDs and lack of sufficiently enough evidence con-
cerning safety of MR scans in the thorax region led to
imaging exclusion zones either defined by study proto-
cols for non-MR conditional pacemakers (e.g. MagnaSafe
Registry) or by manufacturers for certain MR conditionalpacemaker systems (e.g. Medtronic [EnRhythm MRI
EMDR01 and Revo MRI RVDR01 with 5086MRI leads],
Biotronik [Evia/Entovis family with Safio/Solia leads])
[8,12]. In the meantime further extensive bench testing
led to approval outside the US for full body scan with
some of the pacemaker systems named above [13,14].
In 2011 2 condensed summaries of the potential haz-
ards of MR on CIEDs, and the initial experience with MR
conditional pacemakers have been published [15,16]. Jung
et al. concluded: “The availability of MRI-safe technolo-
gies reduces the concerns associated with MRI scanning
in patients with pacemakers and ICDs”. Shinbane et al.
[15] concluded more cautiously that “The design, devel-
opment, study and implementation of cardiovascular MR
conditional devices will continue to require the expertise
and collaboration of multiple disciplines and will need to
prove safety, effectiveness and cost effectiveness in patient
care” [16].
Because of the lack of sufficient data on safety of dedi-
cated diagnostic MR of the heart in patients implanted
with MR conditional pacemakers the purpose of our study
is to analyse safety and potential alterations of electrical
lead parameters in patients implanted with MR condi-
tional EnRhythm/Advisa MRI SureScan pacemakers with
atrial and ventricular CapSure Fix 5086MRI lead (Med-
tronic Inc., Minneapolis, MA, USA) and who underwent
dedicated cardiac MR of the heart imaging at 1.5 T.
Methods
All patients implanted with EnRhythm/Advisa MRI
SureScan pacemaker with 5086MRI leads and who
underwent MR of the heart within the ESTIMATE
Study (Ermittlung von ventrikulären FunktionSparame-
Tern mIttels MagnetresonAnzTomographiE (MRT) wäh-
rend rechtsventrikulärer Stimulation [Magnet resonance
imaging guided assessment of ventricular functional pa-
rameters during right ventricular pacing]) were included
in this analysis. Patients were implanted with permanent
pacemakers according to current guidelines [9,17]. Heart
MR scans were done for study reasons only. The study
was approved by the ethical committee of the govern-
ment of Lower Austria.
The ESTIMATE study was a prospective single center
non-randomized pilot study. Primary endpoint of the
study was the measurement of right and left ventricular
global functional parameters as well as of regional func-
tional parameters assessed at two different pacing rates
(80 bpm and 110 bpm) and a fixed AV delay (110 ms).
Secondary endpoints were assessment of potentially MR
related complications during MR (including the occurrence
of malignant ventricular arrhythmias), and immediately
thereafter as well as in follow-up. Additional secondary
endpoints were comparison of atrial and ventricular sens-
ing amplitudes and pacing capture thresholds assessed
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and 15 months. Within this publication only the results of
the secondary study endpoints of the ESTIMATE Study
are reported.Cardiac MR protocol
All MR scans were performed using an Achieva 1.5
Tesla scanner (release 2.6.3.7, Philips, Netherlands) and
a SENSE cardiac coil (5 elements).
All patients were planned to have MR at a pacing rate
of 80 and 110 bpm. The isocenter landmark was placed
within the thorax. The maximum gradient slew rate
(≤200T/m/s [per axis]) and specific absorption rate
(SAR; ≤2.0 W/kg) complied with the recommendations
given by the pacemaker manufacturer [13,18].
After a reference scan, a balanced fast field echo (B-
FFE) with ECG gating in breath hold technique (10-11s,
1 slice per breathhold) for the horizontal long axis (4-
chamber view) and short axis of both ventricles was per-
formed. The acquisition parameters were as follows: TR
3.5 ms; TE 1.7 ms.; flip angle 70 degrees; slice thickness 8
mm, gap 1mm; acquired voxel size 2.4 × 1.93 mm, recon-
structed voxel size 0.93 × 0.93 mm; 18 heart phases per
RR interval. Both ventricles were covered acquiring 12
slices. The total mean scan duration was 2 minutes per
FFE sequence. The MR study protocol duration was cal-
culated to last 20 to 30 minutes. SAR levels and scan du-
rations were documented for each of the MR sequences.
Previous to MR all PM were programmed into the
SureScan mode according to the recommendations given
by the manufacturer [13,18]. Patient surveillance was
done by using a combination of a telemetry based ECG
and pulse oximetry. All MR scans were supervised by
one of the cardiologists of the study group. After the
MR scan patients were asked if there were any irregular-
ities (e.g. device vibration).EnRhythm/Advisa MRI SureScan pacemaker system
The first permanent pacemaker system ever labelled as
MR conditional was the EnRhythm EMDR01 with
5086MRI leads. The pacemaker system was market re-
leased in Europe in late 2008. At this time there was an
exclusion zone for the placement of the isocenter land-
mark. The landmark had to be outside vertebrae C1 -
Th12. This restriction for the placement of the isocenter
landmark was revised in September 2010 when CE mark
for full body scan was given. The MR conditional Advisa
A3DR01 pacemaker which was market released in Europe
in mid 2009 did not have any restrictions concerning the
isocenter landmark. Virtually no material differences in
components exist between Advisa MRI and EnRhythm
MRI except for the battery, which has a small chemical
difference (information source: personal communicationwith Medtronic). Both pacemakers have the same titanium
can (volume 12.7 ccm, thickness 8 mm).
The CapsureFix® 5086MRI lead, which is a modified
version of CapSureFix® Novus 5076 lead, is a steroid elut-
ing, bipolar, silicone insulated lead with an active fixation
mechanism. The lead body diameter is 2.3 mm. Available
lengths are 45, 52 and 58 cm, respectively [19]. The
major difference to model 5076 is that lead 5086MRI is
eligible for the use with magnet resonance, based on
modified internal wiring composition to decrease the risk
of overheating during an MR scan, and, therefore to re-
duce potentially dangerous heating at the leads tip
[19,20].
Follow-up
Lead measurements (atrial/ventricular sensing [mV],
atrial/ventricular pacing threshold [PCT; Volt/0.4 ms],
pacing impedance [Ohms/5V]) and battery voltage (not
measured at the follow-up (FU) in-between the MR
scans for the different pacing rates) were assessed at 5
in-office follow-ups (immediately before MR, in-between
the scans for the 2 different pacing rates, immediately
post MR, 3 months post MR, and finally 15 months post
MR (3-month FU + 12 months). In addition, clinically
relevant parameters (e.g. amount of atrial/ventricular
pacing) were retrieved from the pacemakers’ statistics.
Statistics
Normally distributed continuous data were reported as
mean ± standard deviation (SD). One-way analysis of
variance was used for comparison of lead measurements
between the different follow-ups. Wilcoxon signed ranks
test was used to compare pre MR data with the data
assessed between the two MR scans (where available)
and at each post MR follow-up. A p < 0.05 was consid-
ered significant. Analyses were performed using the stat-
istical software package IBM SPSS Statistics 20 (IBM
Corporation, Armonk, USA).
Results
Between Aug 2009 and Aug 2011 thirty-eight patients
implanted with the EnRhythm/Advisa MRI SureScan
pacemaker system were enrolled in the ESTIMATE
study. Two male patients did not undergo MR of the
heart within the study (one due to an intrinsic heart rate
above 110 bpm, and one due to an elevated arterial
blood pressure) and were excluded from further ana-
lyses. Therefore, the data of 36 patients are reported.
Thirty-one patients underwent MR at both pacing rates,
5 patients at 110 bpm only because of intrinsic heart
rates above 80 bpm. Table 1 shows the baseline charac-
teristics of the patient cohort. One third of the patients
were female, and the mean age was 69 years. High de-
gree AV block and sick sinus syndrome were the leading
Table 1 Patient Demographics
N %
Total patients 36 100
Female 12 33
Age (years) 69 ± 13 [73]
Pacemaker indication
Higher degree AV block 19 53
Sick sinus syndrome 15 42
Other indication 2 6
Coronary artery disease 13 36
Hypertension 30 83
Diabetes 9 25
Impaired renal function 14 39
Stroke 5 14
Pacemaker
EnRhythm MRI Sure Scan EMDR01 25 69
Advisa MRI Sure Scan A3DR01 11 31
PM Diagnostics
AP (%; [median]) 40 ± 37 [23]
VP (%; [median]) 26 ± 39 [2]
AF-Burden (%; [median]) 17 ± 34 [0]
AF before MR 6 18






Implantation site left pectorally 35 97
Time from implantation (months) 5.3 ± 3.8 [4.5]
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right ventricular lead had been placed in the mid or high
septum (Table 1). Six patients were in atrial fibrillation
(AF) at the beginning of MR, and one patient developed
AF during the MR scan at 110 bpm pacing rate. All pace-
makers were programmed to an asynchronous pacing
mode as intended by the SureScan mode. All patients
with AF at the beginning of MR were programmed to
VOO. In 5 patients VOO mode was programmed due to
other arrhythmias than AF (e.g. frequent atrial extra
beats).
SARmax of the scan sequences was 2.0 W/kg (lowest
1.7; median for all scans 1.9). The cumulative scan dur-
ation was 9 min and 54 sec (median 10 min and 35 sec).
Adverse events
No MR related adverse clinical events occurred. There
were no reported malignant arrhythmias, changes inpatients’ health status, and no device malfunctions ob-
served during and after MR throughout the observa-
tional period. No MR related irregularities (e.g. device
vibration) were reported by any of the patients.
Lead measurements
All patients completed all follow-ups except those pa-
tients who had MR at 110 bpm pacing rate only (n = 5)
and who therefore didn’t have the follow-up in-between
the scans for the different pacing rates. Table 2 displays
all measured parameters from all follow-ups.
Sensing
Atrial leads
No difference for atrial sensing could be shown when
comparing all follow-ups (Table 2). Atrial sensing ampli-
tudes measured at the follow-up in-between the MR
scans decreased by more than 50% but less than 100% in
3 patients (10%). At the follow-up immediately after MR
four patients (11%) had a decrease of the atrial sensing
amplitude by more than 50% but less than 100% as com-
pared to baseline. All of these 4 patients were different
to the patients who showed a sensing decrease in-
between the MR scans. In 1 patient the difference per-
sisted until the 15-month follow-up.
Ventricular leads
Ventricular sensing differed significantly between the
follow-up immediately after MR and baseline (baseline
evaluation: 9.8 ± 5.3 mV [7.5]; FU immediately after MR:
10.3 ± 5.3 mV [8.9]; p < 0.05). Compared over all follow-
ups ventricular sensing was not different between the
follow-ups (Table 2). When comparing the percentages
ventricular sensing values changed, a significant differ-
ence over all follow-ups could be found showing a pro-
portional increase until the 3-month follow-up, and a
proportional decrease afterwards (Table 2).
Two different patients showed RV sensing attenuations




The atrial PCT assessed in-between the two MR studies
was significantly lower than before MR (pre-MR (Volts/
0.4ms) [median]: 0.69 ± 0.22 [0.56]; in-between MR: 0.63 ±
0.19 [0.50]; p < 0.05). All other comparisons showed no
significant difference between the follow-ups (Table 2). An
increase by 100% (max. +0.5V) from the baseline follow-
up to the follow-up immediately after MR of the atrial
pacing threshold was observed in 1 patient. Three pa-
tients (8%), including the one with the early increase, had
an atrial PCT increase by 100% (max. +0.5V) at the 3-
month follow-up compared to baseline. Only 2 of them
Table 2 Measurements before and after MR of the heart
Parameter FU immediately










before (n = 36)
Time from MR
(months)
- - - 2.8 ± 0.7 [3.0] 16.0 ± 3.2 [15.2] -
Time from implantation
(months)
5.3 ± 3.8 [4.5] - - 7.9 ± 3.7 [7.6] 21.2 ± 5.7 [20.7] -
RA Sensing (mV) 2.4 ± 1.3 [2.4] 2.4 ± 1.5 [2.3] 2.3 ± 1.5 [2.0] 2.4 ± 1.3 [2.3] 2.4 ± 1.5 [2.2] n.s.











RA Pimp (Ohms) 511 ± 90 [508] 512 ± 100 [504] 503 ± 90 [478] 504 ± 66 [508] 490 ± 72 [484] n.s.






















RV Pimp (Ohms) 508 ± 75 [504] 516 ± 47 [512]† 515 ± 62 [500] 509 ± 84 [494] 482 ± 58 [488]† n.s.
Battery voltage (V) 3.02 ± 0.03
[3.01]







Value changes (% [median]; compared
with pre MRI FU)
RA sensing 5 ± 49 [0] 4 ± 47 [0] 8 ± 48 [0] 8 ± 43 [5] n.s.
RA PCT -8 ± 17 [0] -6 ± 28 [0] 5 ± 40 [0] -2 ± 38 [0] n.s.
RA Pimp 1 ± 11 [0] -1 ± 11 [0] -0 ± 13 [0] -3 ± 11 [-6] n.s.
RV sensing 9 ± 26 [0] 9 ± 20 [4] 17 ± 39 [8] -3 ± 27 [-6] 0.046
RV PCT -0 ± 33 [0] 7 ± 38 [0] 12 ± 49 [0] 3 ± 39 [0] n.s.
RV PImp 3 ± 7 [4] 2 ± 7 [2] 1 ± 14 [0] -4 ± 10 [-4] 0.015
Battery voltage (V) - -0.3 ± 0.3 [-0.2] -0.4 ± 0.6 [-0.3] -0.6 ± 0.9 [-0.3] n.s.
FU…follow-up; PCT…pacing capture threshold; Pimp…pacing impedance.
*Oneway ANOVA.
† p < 0.05 [Wilcoxon signed Ranks Test].
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follow-up. Of note, the highest atrial pacing threshold
amplitude measured at 0.4 ms impulse duration in the
course after MR was 1.0 Volt (pre-MR: 1.25 V!).
Ventricular leads
Pairwise comparison and one-way ANOVA showed no
significant differences of the ventricular PCT between
the follow-ups (Table 2).
Four patients showed a ventricular PCT increase by
100% (+0.5V [from 0.5V to 1.0 V]) at the follow-up im-
mediately after MR, 2 of these patients showed this in-
crease in-between the scans for the different pacing
rates already. A total of 7 patients (19%) had an increase
of the ventricular PCT by 100% (+0.5V [highest PCT
measured: 1.0V/0.4ms]) at the 3-month follow-up (in-
cluding all 4 patient who showed this increase immedi-
ately after MR), but only 2 of these patients remained
having this increase until the end of the observational
period. Time from pacemaker implantation to MR of the
heart was statistically not different between patients with
and without 100% PCT increase (with PCT increase[median]: 4.3 ± 1.9 [5.1] months; w/o PCT increase [me-
dian]: 5.3 ± 4.1 [4.1] months; p = ns). SARmax and total
scan duration were statistically not different between pa-
tients with and without 100% PCT increase. The SARmax
was 1.93 ± 0.5 in patients without PCT increase, and
1.93 ± 0.5 in patients with 100% PCT increase, respect-
ively (p = ns). Total scan duration did not differ as well
(patients without PCT increase: 10 min 3 sec [median
10 min 35 sec]; patients with PCT increase: 9 min 16
sec [median 10 min 35 sec]; p = ns).
The highest ventricular pacing threshold measured at
the 3-month follow-up was 1.25 Volt/0.4 ms (1 patient),
and was 1.5 Volt/0.4 ms (1 patient) at the 15-month
follow-up, respectively. At the baseline evaluation the
highest ventricular PCT measured was 1.5V/0.4 ms (1
patient).
All of the patients except one with the ventricular
pacing threshold increase by 100% were implanted with
the EnRhythm MRI pacemaker. Two of the patients with
the 100% PCT increase at the 3-month follow-up and 1
patient at the 15-month follow-up had a septal ventricu-
lar lead position.
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Atrial pacing impedance differed significantly between
the baseline follow-up and the last follow-up. Ventricu-
lar pacing impedance differed significantly between the
follow-up in-between the MR scans) and the 15-month
follow-up compared to the baseline follow-up (Table 2).
Comparing all follow-ups no significant differences
could be found. Minimal/maximal values measured were
342 and 896 Ω for atrial leads, and 386 and 832 Ω for
ventricular leads, respectively.
Battery voltage
The battery voltage was significantly different not only
between the baseline and the later follow-ups, but also
compared between the baseline evaluation and the
follow-up that took place immediately after MR
(Table 2). Before MR the minimal/maximal voltage
measured was 2.96/3.08 Volts, and 2.95/3.06 Volts
thereafter, respectively.
Other parameters
The amount of atrial and ventricular pacing did not differ
between the follow-ups at which AP and VP was assessed
(baseline FU, 3-month FU, 15-month FU; Table 3). In
one patient AF occurred during the MR for the 110 bpm
pacing rate. A difference in AF-Burden between the
follow-ups could not be found (Table 3).
Image quality
The implantable pulse generator and the leads cause
various types of artifacts by magnetic field distortion.
Figure 1 shows typical examples. Image quality was
graded as 1 = good, 2 = intermediate, 3 = poor. Image
quality was good to intermediate in 95% of cases and
poor in 5%. However, no cine study was non-diagnostic
as a result of hardware related artifacts.
Discussion
This is the first report on a larger series of patients im-
planted with MR conditional pacemakers with Medtro-
nic 5086MRI leads who underwent diagnostic MR of the
heart. Previously it was demonstrated that MR of the
brain and the lumbar spine in patients implanted with
the EnRhythm MRI SureScan pacemaker system and theTable 3 Pacemaker statistics
Parameter Pre MR FU (n = 36) [median] 3-month
Time from MR (months) -
Atrial pacing (%) 40 ± 37 [23]
Ventricular pacing (%) 26 ± 39 [2]
AF-Burden 17 ± 34 [0]
FU…follow-up.
*Oneway ANOVA.5086MRI leads was safe [21]. During MR of the heart,
and unlike brain MR and lumbar MR the isocenter has
to be placed near or within the region of the pacemaker
system, which may increase the risk of MR related ad-
verse effects on implanted permanent pacemakers. Rod
Gimbel recently reported on chest MR in patients im-
planted with the Advisa pacemakers with 5086MRI leads
[22]. Within this randomized study no MR related ad-
verse events were noted, which can be confirmed by our
study. In the study published by Bruce L. Wilkoff et al.
there was only one patient in whom an increase of
the RV pacing capture threshold was observed at the
1-month post-MR visit [21]. It has been reported that
the SAR limit at the lumbar spine scan was exceeded in
this patient. In the study reported by Rod Gimbel et al.
absolute measured values are not provided. It is reported
that no patient had a ventricular PCT increase by
more than 0.5 Volts. There were no differences in PCT
changes compared to the control group [22].
If the high number of ventricular pacing threshold in-
creases observed in our study is related to the MR pro-
cedure remains unclear since there was no control
group. Compared to other studies with Medtronic de-
vices the observational period of our study was longer
(16 months). Maybe these increases of PCT were not
observed within the other studies because of their rela-
tively short follow-up duration.
Two of the seven patients who showed the noticeable
ventricular pacing capture threshold increase 3 months
after the MR maintained to have this PCT difference
until the last follow-up which took place 16 months after
the MR on average. In these 2 patients the difference
may be due to magnetic resonance. In all the other cases
the differences might partly be dependent on the way
the thresholds were measured (manual PCT measure-
ment with EnRhythm MRI: 0.5 Volt steps!) or may be
purely by chance due to physiological variation. SARmax
and total scan duration showed no significant difference
compared to patients without 100% PCT increase. The
missing association between SAR and changes in lead
specific parameters in our study is in line with previ-
ously published in vivo data [5,23,24].
Since the 3 month FU took place a median of almost 8
months after device implantation, it is unlikely that theFU (n = 36) [median] 15-month FU (n = 36) [median] p = *
2.8 ± 0.7 [3.0] 16.0 ± 3.2 [15.2] -
42 ± 36 [25] 45 ± 36 [40] n.s.
26 ± 38 [3] 30 ± 38 [6] n.s.
15 ± 33 [0] 20 ± 37 [0] n.s.
Figure 1 Device related imaging artifacts. A: Vertical long axis view showing subtle susceptibility artefacts (short arrow) around the
ferromagnetic right ventricular lead (long arrow). In addition, there are prominent off-resonance stripe artifacts in the left ventricle (small arrows)
with no impairment of endocardial border detection. B: Short axis view with the typical signal void caused by the RV lead (short arrow) in the
inferior wall not interfering with the endocardial border. Note the large signal void and circular stripe artifacts caused by the generator (long
arrow) with no interference with the heart.
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part of the healing process after lead implantation.
In a series of 30 patients implanted with MR condi-
tional single or dual chamber pacemakers of a different
manufacturer and who underwent MR of the brain and
lumbar spine, no patient showed an atrial and/or ven-
tricular PCT increase by 100% or more [25]. The way
the pacemakers used within this study measured pacing
thresholds was done in 0.1 Volt steps.
Fact is that only one patient out of the group with
100% PCT increases was implanted with an Advisa pace-
maker (manual PCT measurements in 0.25 Volt steps).
Besides, the maximal increase of either atrial or ventricu-
lar PCT was +0.5V. Septal RV lead position seems not to
have a negative influence on PCT after MR. Nevertheless,
all of the RV PCT changes observed were in clinically ac-
cepted ranges, and – finally - clinically irrelevant. Of
note, the maximum measured ventricular pacing capture
threshold throughout the study was 1.5 Volts/0.4 ms.
Cardiac MR images were somewhat disturbed by the
presence of the IPG and the endocardial leads but of-
fered sufficiently high quality as needed with our ana-
lyses (Figure 1). IPG and lead dependent artifacts and
their impact on image quality were extensively analysed
in a quality evaluation of a large series of cardiac magnet
resonance images drawn from a multicenter trial which
was conducted to demonstrate the safety and effective-
ness of the Advisa MRI pacemaker in an MR environ-
ment [22,26]. The recently published results show
diagnostic quality in the vast majority of images – as it
was within our study [26].
Limitations
There are some limitations with our study. One limita-
tion is the small number of patients enrolled, and thesecond limitation is the non-randomized study design.
Another limitation is that the enrolled patients had 2
different pacemakers implanted. Therefore, it remains
unclear, if the pacing threshold changes observed were
MR related or - for example - dependent on the pace-
maker specific pacing capture threshold measurement.
Conclusion
The results of our study suggest the MR conditional
EnRhythm/Advisa pacemaker system to be safe when
undergoing diagnostic MR of the heart. Except for ven-
tricular PCT the results of our study demonstrate stable
lead measurements after MR of the heart performed in
patients with specifically for the MR environment de-
signed dual chamber pacemaker systems. The relatively
large number of observed ventricular PCT increases
may be specific for the manual PCT assessment with
EnRhythm MRI pacemakers, but were all clinically
irrelevant. No MR related adverse device related or other
adverse events occurred within our study.
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